Technical Analysis for AGIO - Agios Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
D 48.59 -2.27% -1.13
AGIO closed down 2.27 percent on Tuesday, July 27, 2021, on 1.65 times normal volume. The stock fell below its 200 day moving average, damaging its long-term outlook by crossing under that critical trendline. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.
Earnings due: Jul 28
*** please verify all earnings dates ***

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Down Down Down
Historical AGIO trend table...

Date Alert Name Type % Chg
Fell Below 200 DMA Bearish 0.00%
Lower Bollinger Band Walk Weakness 0.00%
Multiple of Ten Bearish Other 0.00%
Below Lower BB Weakness 0.00%
Down 3 Days in a Row Weakness 0.00%
Down 4 Days in a Row Weakness 0.00%
Down 5 Days in a Row Weakness 0.00%
Lower Bollinger Band Touch Weakness 0.00%
Oversold Stochastic Weakness 0.00%
Calm After Storm Range Contraction -2.27%
Older End-of-Day Signals for AGIO ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
200 DMA Support about 9 hours ago
1.5x Volume Pace about 13 hours ago
Down 3% about 13 hours ago
Down 2 % about 13 hours ago
Down 1% about 13 hours ago
View Earlier Intraday Alerts

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.


Agios Pharmaceuticals, Inc. Description

Agios Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics in the field of cancer metabolism and inborn errors of metabolism (IEMs) in the United States. Its products include AG-221, an oral inhibitor of the mutated isocitrate dehydrogenase (IDH) 2 protein for the treatment of patients with cancers that harbor IDH2 mutations, as well as for the Type II D-2 hydroxyglutaric aciduria treatment; AG-120, an oral inhibitor of the mutated IDH1 protein for the treatment of patients with cancers that harbor IDH1 mutations; and enzyme glutaminase that converts the nutrient glutamine into the metabolite glutamate. The company's products also comprise AG-348, an oral small molecule activator of PKR enzyme for the treatment of patients with pyruvate kinase deficiency. It has a collaboration agreement with Celgene Corporation. The company was founded in 2007 and is based in Cambridge, Massachusetts.


Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Cancer Acid Cancers Hydrogen Metabolism Organic Chemistry Inborn Errors Of Metabolism Glutamate Agios Pharmaceuticals Glutaminase Pyruvate Kinase Deficiency

Is AGIO a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 62.155
52 Week Low 32.47
Average Volume 691,169
200-Day Moving Average 49.26
50-Day Moving Average 56.47
20-Day Moving Average 54.98
10-Day Moving Average 53.62
Average True Range 1.95
ADX 18.81
+DI 12.50
-DI 39.63
Chandelier Exit (Long, 3 ATRs) 52.73
Chandelier Exit (Short, 3 ATRs) 53.70
Upper Bollinger Bands 60.43
Lower Bollinger Band 49.53
Percent B (%b) -0.09
BandWidth 19.83
MACD Line -1.69
MACD Signal Line -0.83
MACD Histogram -0.8611
Fundamentals Value
Market Cap 3.37 Billion
Num Shares 69.3 Million
EPS -6.67
Price-to-Earnings (P/E) Ratio -7.28
Price-to-Sales 15.74
Price-to-Book 6.52
PEG Ratio 0.00
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 52.19
Resistance 3 (R3) 52.35 51.30 51.59
Resistance 2 (R2) 51.30 50.39 51.23 51.39
Resistance 1 (R1) 49.95 49.82 49.43 49.79 51.19
Pivot Point 48.90 48.90 48.64 48.83 48.90
Support 1 (S1) 47.55 47.99 47.03 47.39 45.99
Support 2 (S2) 46.50 47.42 46.43 45.79
Support 3 (S3) 45.15 46.50 45.59
Support 4 (S4) 44.99